Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Shares Outstanding (Weighted Average) (2021 - 2025)

PAVmed has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $670466.0 for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $670466.0 for Q4 2025, up 107.96% from a year ago — trailing twelve months through Dec 2025 was $670466.0 (up 107.96% YoY), and the annual figure for FY2025 was $670466.0, up 107.96%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $670466.0 at PAVmed, down from $21.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for PAVM hit a ceiling of $89.8 million in Q3 2022 and a floor of $322407.0 in Q4 2024.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $13.9 million (2025), compared with a mean of $35.6 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 95.54% in 2024 and later soared 107.96% in 2025.
  • PAVmed's Shares Outstanding (Weighted Average) stood at $77.5 million in 2021, then crashed by 92.34% to $5.9 million in 2022, then grew by 21.78% to $7.2 million in 2023, then tumbled by 95.54% to $322407.0 in 2024, then soared by 107.96% to $670466.0 in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $670466.0 (Q4 2025), $21.6 million (Q3 2025), and $16.0 million (Q2 2025) per Business Quant data.